Foralumab
Appearance
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CD3 epsilon |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
(what is this?) (verify) |
Foralumab is a fully human monoclonal antibody that binds to CD3 epsilon.[1] Also called TZLS-401, it is currently in clinical development by Tiziana Life Sciences for treatment of Crohn's disease and other autoimmune diseases.[2] However foralumab did not show efficacy for Crohn's disease.[3]
It is currently in clinical development by Tiziana Life Sciences for treatment of secondary progressive Multiple sclerosis.[4][5]
References
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.
- ^ "Foralumab". Tiziana Life Sciences plc.
- ^ Giuffrida P, Di Sabatino A (September 2020). "Targeting T cells in inflammatory bowel disease". Pharmacological Research. 159: 105040. doi:10.1016/j.phrs.2020.105040. PMID 32585338.
- ^ Wexler M. "2nd SPMS Patient Sees Clinical Gains With Foralumab Treatment". Multiple Sclerosis News Today. Retrieved 16 June 2022.
- ^ "Intranasal Foralumab Provides Neuroimaging and Clinical Improvements in Secondary Progressive Multiple Sclerosis". practicalneurology. Retrieved 6 August 2022.